ArticleDiscover oncology2026
Identification of TRPM4 related genes in LUAD by RNA seq and spatial transcriptomics.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundSodium overload-induced cell death is a novel mode of cell death that differs from other modes and is a very promising new target for cancer therapy. In addition, sodium overload-induced cell death plays a crucial role in cancer progression and patient prognosis. Therefore, our study aims to establish a survival prediction model for patients with lung adenocarcinoma (LUAD) based on related genes, exploring the immune landscape and providing new insights for future individualized treatment protocols.
methodWe analyzed the expression and clinical significance of TRPM4-related genes in LUAD using data from TCGA and GEO databases. We used transcriptomics, immune infiltration assays, and spatial transcriptomics (ST). Kaplan-Meier survival analysis was used to assess the relationship between TRPM4-related genes and prognosis. Enrichment analyses identified biological processes and pathways associated with TRPM4 and also assessed its relationship with the immune microenvironment and drug sensitivity.
resultsWe identified 19 oncogenic driver genes and modeled proportional hazard regression. The results showed that the survival rate of the high-risk group was significantly reduced in both the training and testing sets. Additionally, the high-risk group exhibited lower levels of immune cell infiltration and immune checkpoint expression compared to the low-risk group. Based on 19 genes, LMNA, PPP2R1A, and PDXK were identified as key genes by single-cell sequencing and spatial transcriptome sequencing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.